Blurton-Jones lab presents at ADPD 2025 in Vienna, Austria

Dr. Mathew Blurton-Jones and Jean Paul Chadarevian were invited to share their research at this year’s ADPD 2025 (April 1-5) International Conference on Alzheimer’s and Parkinson’s Diseases.

Dr. Mathew Blurton-Jones was invited to moderate the session on cell replacement therapy & diagnostics, where he presented key findings highlighting the differences between CNS-wide engrafted human monocytes and iPSC-microglia.  Dr. Jean Paul Chadarevian was also selected to present his research harnessing human iPSC-microglia for CNS-wide delivery of therapeutic peptides.

Congratulations to all the attendees and participants of ADPD 2025!

Blurton-Jones lab attends Emerging Scientists Symposium at UCI

The UCI MIND trainee-led organization ReMIND held its annual Emerging Scientists Symposium at the UCI Student Center. This yearly event gives UCI MIND graduate students, medical students, and post-doctoral scholars opportunities to get out of the laboratory to present their work through posters and oral presentations, to network with and learn from each other, and to generally stay excited about research and the progress we are making toward understanding and discovering solutions for Alzheimer’s disease and related disorders (ADRD) research. Congratulations to Zahara Keulen, Dr. Ghazaleh Eskandari-Sedighi, and Dr. Jean Paul Chadarevian on your selection and presentations!

Read more about this important event: https://mind.uci.edu/remind_train/

MBJ Lab attends Keystone Symposia

Dr. Jean Paul Chadarevian and Joia K. Capocchi attend 2024 Keystone Symposia on Neurodegeneration in Santa Fe, NM where Jean Paul presented, “Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy“.

MBJ Lab attends ISMND 2024 Conference

Dr. Blurton-Jones (Examining the therapeutic potentical of microglial transplantation in chimeric models of AD and FTD) and Dr. Davtyan (Human Monocytes remain transcrptionally and functionally distinct from microglia despite long-term brain engraftment) presented at the International Society of Molecular Neurodegeneration 2024 conference on aging, immunity, and peripheral factors in neurodegenerative disease in Seoul, Korea.

  

Congratulations on your successful defense Dr. Sepideh Kiani Shabestari

Examining the Diverse Pathological Consequences of Microglial Absence 

Our understanding of microglia, the principal immune cells of the central nervous system (CNS), continues to evolve as new models and approaches shift our perception of these intriguing cells. Previously envisioned as passive guardians of the brain, microglia have since been shown to play critical roles in development, neuroplasticity, and neurological disease.To further understand the role of microglia in AD and the impact of microglial absence on the aging brain, my thesis studies utilized ‘FIRE mice’, a genetic model that lacks microglia. FIRE mice harbor a homozygous deletion within the Fms intronic regulatory element (FIRE) super-enhancer, leading to a loss of CSF1R expression and congenital absence of microglia.  To examine the role of microglia in AD pathogenesis, I crossed FIRE mice with 5xfAD mice that develop robust beta-amyloid plaque pathology. Remarkably, I found that absence of microglia promotes the development of cerebral amyloid angiopathy (CAA), brain calcification, and cerebral hemorrhages in AD mice. Importantly, transplantation of wildtype microglia prevents each of these pathological changes. To determine whether microglia absence alone can also induce pathological changes within the aging brain, I further examined 9-10 month-old FIRE mice in comparison to wildtype littermates and explored the impact of postnatal microglial transplantation, demonstrating that prolonged absence of microglia leads to the development of astrogliosis, calcification, and seizures, mimicking many of the pathological features of a rare human primary microgliopathy.  Taken together, my thesis studies have revealed important roles for microglia in protecting the brain against age- and disease-related development of vascular, and white matter pathologies. These findings not only deepen our understanding of microglia’s roles in neurodegenerative diseases, but also provide initial evidence to support microglial transplantation as a viable therapeutic approach for a variety of neurodegenerative diseases.